Pharmacologic Characterization of TQ 05310, a Potent Inhibitor of Isocitrate Dehydrogenase 2 ( IDH 2) R140Q and R172K Mutants

Cancer Science - United States
doi 10.1111/cas.14152
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase (IDH) Mutations in Gliomas

Clinical Cancer Research
Cancer ResearchOncology
2019English

2-Hydroxyglutarate (2-Hg); Isocitrate Dehydrogenase 1 (IDH1)

Science-Business eXchange
2013English

Exogenous Gene Transmission of Isocitrate Dehydrogenase 2 Mimics Ischemic Preconditioning Protection

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2018English

Preclinical Characterization of Anlotinib, a Highly Potent and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor

Cancer Science
Cancer ResearchMedicineOncology
2018English

Thrombospondin-2: A Potent Endogenous Inhibitor of Tumor Growth and Angiogenesis

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1999English

Interstitial Deletion of the Long ARM of Chromosome 2: A Dose Study on Isocitrate Dehydrogenase 1

Japanese journal of human genetics
1988English

Interstitial Deletion of the Long Arm of Chromosome 2 With Normal Levels of Isocitrate Dehydrogenase.

Journal of Medical Genetics
Genetics
1989English

Discovery of N-(2-Aminophenyl)-4-(Bis(2-Chloroethyl)amino)Benzamide as a Potent Histone Deacetylase Inhibitor

Frontiers in Pharmacology
Pharmacology
2019English

Characterization ofEscherichia coliNull Mutants for Glutaredoxin 2

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy